Readouts from two phase 3 clinical trials demonstrated that Eli Lilly and Company’s Ultra Rapid Lispro (URLi) met the primary efficacy endpoint of non-inferior A1C reduction from baseline compared to Humalog (insulin lispro) and also demonstrated significantly improved post-meal glucose control in people with type 1 and type 2 diabetes.
![Design thinking als contentmarketeer inzetten [voorbeelden & tips]](https://www.pharmamarketeer.nl/wp-content/uploads/2024/11/business-team-working-in-a-start-up-office-2023-11-27-05-22-22-utc-1-80x60.jpg)
Reageer